Search clinical trials for: SM3321

Total 18 results

Beijing StarMab Biomed Technology Ltd

Recruiting

Clinical Study of SM3321 With Solid Tumors

Locally Advanced or Metastatic Solid Tumors

China
Immutep S.A.S.
Umanis

Completed

IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC)

Stage IV Renal Cell Carcinoma

France
Centre Hospitalier Universitaire Vaudois
Immutep S.A.S.

Terminated

Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients (LAG-3/IMP321)

Melanoma

Switzerland
Immutep S.A.S.
Umanis

Completed

IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma

Metastatic Breast Cancer

France
Nordic Bioscience A/S
Novartis

Completed

Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis

Osteoarthritis

Denmark, Estonia, Hong Kong, Poland, Romania, Czechia
Immutep S.A.S.
SGS Aster-Cephac (CRO)

Completed

Phase I Study of IMP321 Given Alone or as an Adjuvant to a Reference Flu Antigen

Healthy

France
Novartis

Completed

Drug Interaction of SMC021 With Concomitant Antacid (Calcium Carbonate/Magnesium Hydroxide).

Health Postmenopausal Women

Denmark
Nordic Bioscience A/S
Novartis

Completed

A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D

Osteoporosis

France, Denmark, United States, Brazil, China, Czech Republic, Estonia, Hong Kong, Italy, Lithuania, Poland, Romania
Immutep Australia Pty. Ltd.

Completed

Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma (TACTI-mel)

Stage IV Melanoma | Stage III Melanoma

Australia
Immutep S.A.S.
Merck Sharp & Dohme LLC

Active, not recruiting

Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (TACTI-002)

NSCLC | HNSCC

Spain, United States, United Kingdom, Australia, Ukraine
Immutep S.A.S.

Withdrawn

A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel (AIPAC-002)

Metastatic Breast Cancer
Institut für Klinische Krebsforschung IKF GmbH...

Recruiting

Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors

Solid Tumors | Peritoneal Carcinomatosis

Germany
Immutep S.A.S.

Completed

IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma

Adenocarcinoma Breast Stage IV

Netherlands, United Kingdom, France, Belgium, Germany, Hungary, Poland
Cliniques universitaires Saint-Luc- Université...
Immutep S.A.S.

Terminated

Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides

Melanoma

Belgium
Immutep S.A.S.
Merck Sharp & Dohme LLC

Recruiting

Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC (TACTI-003)

HNSCC

United States, Belgium, Spain, United Kingdom, Denmark, Germany, Australia, Romania, Ukraine
Immutep S.A.S.

Recruiting

Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy (AIPAC-003)

Breast Carcinoma

Spain, United States, Belgium
Immutep S.A.S.
SGS Aster-Cephac (CRO)

Completed

A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321

Healthy

France
Prof. Serge Leyvraz

Completed

Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma

Melanoma (Skin)

Switzerland

3

Subscribe